Case Studies

Challenge: A leading U.S. children’s hospital commissioned an independent review of a novel therapeutic approach for rare neonatal diseases. The principal investigator (PI) - a highly regarded,...

Challenge: A privately held US-based biotech company specializing in pain therapeutics had developed a cutting-edge drug discovery platform utilizing multi-omic, tissue-specific datasets. This...

Synopsis For Technology Transfer Offices (TTOs), evaluating and prioritizing intellectual property (IP) portfolios is a critical step in determining the best allocation of internal funding and...

Challenge: An AI-driven drug discovery company requested an expert third party assessment of the attractiveness and risks of a particular discovery strategy focused on a dual tyrosine kinase...

Challenge: A mid-sized pharmaceutical company was considering the option of expanding into developing gene therapies for CNS diseases. Alacrita was asked to help them evaluate and prioritize the...

Challenge: An early-stage biotech company asked Alacrita to identify drug program assets that had been discontinued from further development due to neutralizing antibodies (Nabs) but not due to...

Challenge A company had developed a technology for overcoming solubility issues in drug formulations and was planning to develop a small number of 505 (b)(2) candidate molecules. The client had...

Project Challenge: A European biotech company was developing next-generation ADC payloads with at least as good intracellular cytotoxicity properties as other payloads used in ADCs, but with a much...

Challenge: A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over the counter...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...

Challenge A European clinical-stage biopharma company was developing a recombinant protein for multiple immune-driven indications and required support in shaping its future business strategy....

Challenge: Our client was advising principal investors on a possible transaction to cover the development and commercialization of a product targeting chemotherapy-induced anemia (CIA). Alacrita was...